![](https://investorshub.advfn.com/uicon/78991.png?cb=1630499252)
Wednesday, October 07, 2015 5:30:56 AM
http://wsw.com/webcast/cc/mstx/register.aspx?conf=cc&page=mstx&url=http%3A//wsw.com/webcast/cc/mstx/
Target price vs. sales in SCD
Some analysts say that the sales of vepoloxamer in SCD could be in the range of $300-800 million per year.
the Price/Sales ratio or P/S in healthcare sector is a number between 3 to 20. 3 for big company, 20 for small company.
Also if you suppose a P/S very conservati of 5 you have a market capitalisation in the range of $1.5-4 billion.
This market cap. gives a pps in the range $8-$23 share.
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM